Topics include: how the FDA can speed up COVID-19 recovery, the likely FDA Commissioner nominee, FDA’s Digital Health Center of Excellence, patient safety issues like LDT oversight, device servicing, and regenerative medicine, 2022 user fee reauthorization negotiations and more.
POLITICO
Get the Future Pulse newsletter
Email
Sign Up
By signing up you agree to receive email newsletters or updates from POLITICO and you agree to our privacy policy and terms of service. You can unsubscribe at any time and you can contact us here. This sign-up form is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Big Idea
COVID RESPONSE SHOWS AI S LIMITS: Hospitals are learning the limits of AI as they trot out new tech during the pandemic, whether to triage patients or identify potential drug therapies. And it’s not the panacea some had hoped for.
At the beginning of February, the US Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) appointed Professor Kevin Fu as the first ever Acting Director.
Legal Disclaimer
You are responsible for reading, understanding and agreeing to the National Law Review s (NLR’s) and the National Law Forum LLC s Terms of Use and Privacy Policy before using the National Law Review website. The National Law Review is a free to use, no-log in database of legal and business articles. The content and links on www.NatLawReview.com are intended for general information purposes only. Any legal analysis, legislative updates or other content and links should not be construed as legal or professional advice or a substitute for such advice. No attorney-client or confidential relationship is formed by the transmission of information between you and the National Law Review website or any of the law firms, attorneys or other professionals or organizations who include content on the National Law Review website. If you require legal or professional advice, kindly contact an attorney or other suitable professional advisor.